115 related articles for article (PubMed ID: 16098253)
1. Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study.
Leichman CG; Benedetti JK; Zalupski MM; Hochster H; Shields AF; Lenz HJ; Wade Iii JL; Bearden Iii JD; Macdonald JS
Clin Colorectal Cancer; 2005 Jul; 5(2):119-23. PubMed ID: 16098253
[TBL] [Abstract][Full Text] [Related]
2. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
Benson AB
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):28-34. PubMed ID: 9830622
[TBL] [Abstract][Full Text] [Related]
3. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ
J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
[TBL] [Abstract][Full Text] [Related]
4. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
Jäger E; Heike M; Bernhard H; Klein O; Bernhard G; Lautz D; Michaelis J; Meyer zum Büschenfelde KH; Knuth A
J Clin Oncol; 1996 Aug; 14(8):2274-9. PubMed ID: 8708717
[TBL] [Abstract][Full Text] [Related]
5. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer.
Hansen RM; Ryan L; Anderson T; Krzywda B; Quebbeman E; Benson A; Haller DG; Tormey DC
J Natl Cancer Inst; 1996 May; 88(10):668-74. PubMed ID: 8627643
[TBL] [Abstract][Full Text] [Related]
6. Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer.
Regazzoni S; Pesce G; Marini G; Cavalli F; Goldhirsch A
Ann Oncol; 1996 Oct; 7(8):807-13. PubMed ID: 8922194
[TBL] [Abstract][Full Text] [Related]
7. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
Ducreux M; Bouche O; Pignon JP; Mousseau M; Raoul JL; Cassan P; Leduc B; Berger C; Dunant A; Fournet J; Bedenne L;
Oncology; 2006; 70(3):222-30. PubMed ID: 16816536
[TBL] [Abstract][Full Text] [Related]
8. 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer.
Rougier P; Paillot B; LaPlanche A; Morvan F; Seitz JF; Rekacewicz C; Laplaige P; Jacob J; Grandjouan S; Tigaud JM; Fabri MC; Luboinski M; Ducreux M
Eur J Cancer; 1997 Oct; 33(11):1789-93. PubMed ID: 9470834
[TBL] [Abstract][Full Text] [Related]
9. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
Gamelin E; Delva R; Jacob J; Merrouche Y; Raoul JL; Pezet D; Dorval E; Piot G; Morel A; Boisdron-Celle M
J Clin Oncol; 2008 May; 26(13):2099-105. PubMed ID: 18445839
[TBL] [Abstract][Full Text] [Related]
10. Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
Kabbinavar FF; Ellis LM
Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S69-73. PubMed ID: 15479482
[TBL] [Abstract][Full Text] [Related]
11. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
[TBL] [Abstract][Full Text] [Related]
12. A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.
Whitehead RP; Benedetti JK; Abbruzzese JL; Ardalan B; Williamson S; Gaynor ER; Balcerzak SP; Macdonald JS
Invest New Drugs; 2004 Nov; 22(4):467-73. PubMed ID: 15292717
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
[TBL] [Abstract][Full Text] [Related]
14. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
[TBL] [Abstract][Full Text] [Related]
15. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
16. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
Graeven U; Arnold D; Reinacher-Schick A; Heuer T; Nusch A; Porschen R; Schmiegel W
Onkologie; 2007 Apr; 30(4):169-74. PubMed ID: 17396039
[TBL] [Abstract][Full Text] [Related]
17. A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil.
Anderson N; Lokich J; Moore C; Bern M; Coco F
Cancer Invest; 1999; 17(8):586-93. PubMed ID: 10592766
[TBL] [Abstract][Full Text] [Related]
18. The EORTC GI group experience with high-dose infusional 5-FU in colorectal cancer.
Blijham GH
J Infus Chemother; 1996; 6(3):114-7. PubMed ID: 9229320
[TBL] [Abstract][Full Text] [Related]
19. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
20. Continuous infusion of 5-fluorouracil with versus without low-dose, consecutive administration of cisplatin in advanced colorectal cancer. A prospective randomized phase II study.
Nakata B; Sowa M; Tsuji A; Kamano T; Sasaki K; Fukunaga Y; Takahashi M; Tsujitani S; Mikami Y; Mitachi Y; Nishimura S; Araki H; Yamamitsu S; Hirakawa K; Tominaga S; Shirasaka T; Inokuchi K
J Exp Clin Cancer Res; 2007 Mar; 26(1):51-60. PubMed ID: 17550132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
